Black Hawk Acquisition Corp BKHA

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) Nasdaq

We are a Cayman Islands company incorporated on September 28, 2023, as an exempted company with limited liability. We chose to incorporate in the Cayman Islands due to (i) its tax-neutrality, which allows international transactions to be structured efficiently without an additional layer of tax and (ii) simplicity of establishment and flexibility of administration, including easy migration to another jurisdiction, the existence of statutory procedures for merger or consolidation, and no takeover code or bespoke public company filing requirements.

We were formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities, which we refer to as a "target business." On April 26, 2025, we entered into a Business Combination Agreement with Vesicor Therapeutics, Inc. and BH Merger Sub, Inc., pursuant

Last close 11.99 2026-09-02
Market cap $49.8M 2026-05-31 share count
52-week range 11.00 - 13.10

Valuation FY2025 figures against the last close

P/S
P/E
P/FCF
EV/EBITDA
Dividend yield
Diluted EPS

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023
SG&A $795.5K$492.1K
Operating income -$915.5K-$576.1K
Interest expense $15.5K$2.5M
Net income $1.3M$1.9M

Balance sheet

Fiscal year FY2025FY2024FY2023
Cash and equivalents $0$0$125.1K
Total current assets $50.8K$314.1K$156.0K
Other intangibles $5.0M
Total assets $23.9M$72.1M$263.0K
Accounts payable $15.5K
Total current liabilities $1.5M$71.0K$256.9K
Total liabilities $3.9M$2.5M$256.9K
Retained earnings -$3.9M-$2.2M-$18.9K
Total equity -$3.8M-$2.2M$6.1K

Cash flow

Fiscal year FY2025FY2024FY2023
Operating cash flow -$650.3K-$553.7K
Investing cash flow $50.3M-$69.3M
Financing cash flow -$49.8M$70.0M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001829126-26-004046.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $236.38B 30.7x 10.0%
GILD GILEAD SCIENCES, INC. $187.23B 22.3x 2.4%
MRNA Moderna, Inc. $58.11B -39.9%
RVMD Revolution Medicines, Inc. $45.01B
BIIB BIOGEN INC. $32.60B 25.1x 2.2%
SCNI Scinai Immunotherapeutics Ltd. $25.80B 99.2%
NBIX NEUROCRINE BIOSCIENCES INC $15.82B 33.3x 21.4%
EXEL EXELIXIS, INC. $14.62B 21.2x 7.0%